Sort
82,697 grants matching “vaccine development”
Cell entry, cross-species transmission and pathogenesis of novel coronavirus from
$748,081Ralph S Baric · Univ Of North Carolina Chapel Hill · R01 · FY2023 · AI
Cell entry, cross-species transmission and pathogenesis of novel coronavirus from
$748,081Ralph S Baric · Univ Of North Carolina Chapel Hill · R01 · FY2024 · AI
Cell entry, cross-species transmission and pathogenesis of novel coronavirus from
$748,081Ralph S Baric · Univ Of North Carolina Chapel Hill · R01 · FY2022 · AI
HIV-1 Genetic Variation in Infected Individuals
$748,076Frank Maldarelli · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Systems Biology Approach to Analysis of Vaccine Response in Healthy Individuals
$748,045Anna Karolina Palucka · Baylor Research Institute · U19 · FY2014 · AI
Anti-flavivirus B cell response analysis to aid vaccine design
$748,034Yuxing Li · University Of Maryland Baltimore · R01 · FY2025 · AI
Bi-functional Polymer-Attached Inhibitors of Influenza Viruses
$747,992Jianzhu Chen · Massachusetts Institute Of Technology · U01 · FY2009 · AI
Research Project 1 - The pregnancy ImmunOME
$747,949Andrea Goldberg Edlow · Massachusetts Institute Of Technology · U19 · FY2023 · AI
Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS
$747,940Theodora Hatziioannou · Aaron Diamond Aids Research Center · R01 · FY2013 · AI
Characterizing Host-Virus Interactions in a New HIV Model Organism
$747,862Sara Sawyer · University Of Colorado · R01 · FY2022 · OD
NIAID Process Development and Analytical Support for Development of HIV Vaccines
$747,853Thomas Hassell · International Aids Vaccine Initiative · N01 · FY2018 · AI
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
$747,848Klaus J Frueh · Oregon Health & Science University · R01 · FY2020 · AI
Prophylactic oral vaccination for SIV and SHIV infections and AIDS prevention
$747,799Anna Aldovini · Boston Children'S Hospital · R01 · FY2018 · DE
Immune correlates of tuberculosis and non-tuberculosis infectious morbidity in Southern African HIV-exposed, uninfected infants.
$747,678Kathleen Powis · Massachusetts General Hospital · R01 · FY2021 · AI
Southwest EDRN Clinical Validation Center for Head and Neck Cancer
$747,673Karen Sue Anderson · Arizona State University-Tempe Campus · U01 · FY2023 · CA
Multiplex Serodiagnostic Protein Microarray
$747,612Philip Louis Felgner · University Of California-Irvine · U01 · FY2009 · AI
Project 3
$747,608Uriel Dan Kitron · University Of California At Davis · P01 · FY2016 · AI
Comprehensive antigenic mapping of the human anti-peanut IgE antibody response
$747,580Scott Alan Smith · Vanderbilt University Medical Center · R01 · FY2025 · AI
Animal Core
$747,544David S Perlin · Columbia University Health Sciences · U54 · FY2009 · AI
A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses
$747,542Victor Robert Defilippis · Oregon Health & Science University · R01 · FY2024 · AI
Dissemination of the Cardiovascular Risk Service (CVRS Live)
$747,539Korey A Kennelty · University Of Iowa · R01 · FY2019 · HL
Immunotherapeutics vs Ebola Sudan: Development, Structural & Functional Analysis
$747,538Erica Ollmann Saphire · Scripps Research Institute, The · U01 · FY2009 · AI
Quantitative Detection of Coronary Microvascular Dysfunction in Long COVID Patients using a Comprehensive, Rapid, Free-Breathing Cardiovascular MRI
$747,523Daniel Kim · Northwestern University At Chicago · R01 · FY2025 · HL
HIV-1 vaccine-elicited antibodies target envelope glycans
$747,507Kevin O Saunders · Duke University · R01 · FY2023 · AI
Immune Responses Associated with Malaria Infection and Immune Protection - Project 1
$747,401Kenneth D Stuart · Seattle Biomedical Research Institute · U19 · FY2017 · AI